MIRM Mirum Pharmaceuticals Inc

$71.52

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.

Website: https://www.mirumpharma.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1759425
Address
950 TOWER LANE, SUITE 1050, FOSTER CITY, CA, US
Valuation
Market Cap
$1.93B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
8.57
Performance
EPS
$-1.85
Dividend Yield
—
Profit Margin
-26.10%
ROE
-37.10%
Technicals
50D MA
$45.89
200D MA
$42.72
52W High
$54.23
52W Low
$23.14
Fundamentals
Shares Outstanding
49M
Target Price
$63.78
Beta
1.01

MIRM EPS Estimates vs Actual

● Estimated
● Actual

MIRM News & Sentiment

Aug 07, 2025 • Zacks Commentary SOMEWHAT-BULLISH
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.
Aug 06, 2025 • Zacks Commentary NEUTRAL
Mirum Pharmaceuticals, Inc. ( MIRM ) Reports Q2 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +61.29% and +17.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 31, 2025 • Zacks Commentary NEUTRAL
Agios Pharmaceuticals ( AGIO ) Reports Q2 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 30, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Mirum Pharmaceuticals, Inc. ( MIRM ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jul 17, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.
Jun 24, 2025 • Zacks Commentary SOMEWHAT-BULLISH
EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch
GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.
Sentiment Snapshot

Average Sentiment Score:

0.072
50 articles with scored sentiment

Overall Sentiment:

Neutral

MIRM Reported Earnings

Feb 26, 2025
Dec 31, 2024 (Pre market)
-0.24 Surprise
  • Reported EPS: $-0.49
  • Estimate: $-0.25
  • Whisper: —
  • Surprise %: -98.7%
Nov 04, 2024
Sep 30, 2024 (Post market)
0.15 Surprise
  • Reported EPS: $-0.30
  • Estimate: $-0.45
  • Whisper: —
  • Surprise %: 33.8%
Aug 07, 2024
Jun 30, 2024 (Post market)
-0.05 Surprise
  • Reported EPS: $-0.52
  • Estimate: $-0.47
  • Whisper: —
  • Surprise %: -10.6%
May 08, 2024
Mar 31, 2024 (Post market)
-0.06 Surprise
  • Reported EPS: $-0.54
  • Estimate: $-0.48
  • Whisper: —
  • Surprise %: -12.5%
Feb 28, 2024
Dec 31, 2023 (Post market)
-0.42 Surprise
  • Reported EPS: $-0.66
  • Estimate: $-0.24
  • Whisper: —
  • Surprise %: -175.0%
Nov 02, 2023
Sep 30, 2023 (Post market)
0.06 Surprise
  • Reported EPS: $-0.57
  • Estimate: $-0.63
  • Whisper: —
  • Surprise %: 9.5%
Aug 03, 2023
Jun 30, 2023 (Post market)
-1.14 Surprise
  • Reported EPS: $-1.94
  • Estimate: $-0.80
  • Whisper: —
  • Surprise %: -142.5%
May 04, 2023
Mar 31, 2023 (Post market)
0.14 Surprise
  • Reported EPS: $-0.80
  • Estimate: $-0.94
  • Whisper: —
  • Surprise %: 14.9%
Mar 08, 2023
Dec 31, 2022 (Post market)
0.03 Surprise
  • Reported EPS: $-0.99
  • Estimate: $-1.02
  • Whisper: —
  • Surprise %: 2.9%

Financials